Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy
Open Access
- 31 January 2022
- journal article
- research article
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (7) , 915-923
Abstract
Aim: To study neurotransmitter status in children with early epileptic and developmental and epileptic encephalopathy (DEE) and to explore the clinical response to dopaminergic and serotoninergic therapies in a group of patients.Method: Two hundred and five patients (111 males [54.1.%] and 94 females [45.9%], mean age 10 months at the onset of epilepsy [SD 1 year 1 month], range 0–3 year) with epileptic encephalopathy/DEE were recruited, including those with West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, myoclonic encephalopathy in non‐progressive disorders, infantile spasms, Doose syndrome, Lennox–Gastaut syndrome, Landau–Kleffner syndrome, and those unclassified. Cerebrospinal fluid (CSF) neurotransmitter studies and patients' medical records were reviewed. Additionally, we present clinical data of 10 patients with low CSF neurotransmitter levels who received dopaminergic/serotoninergic treatments.Results: Abnormal neurotransmitter values were identified in 68 (33%) patients. 5‐Hydroxyindoleacetic acid (5‐HIAA) deficit was the most prevalent alteration (91%). Low CSF 5‐HIAA levels were significantly higher in 1‐ to 3‐year‐old children. A negative significant correlation was found between 5‐HIAA levels and epilepsy duration before CSF study (Spearman's ρ=−0.191, p=0.007). Abnormalities in deep grey matter were associated with low levels of CSF homovanillic acid and 5‐HIAA. Ten patients with low CSF neurotransmitter levels received dopamine and/or serotonin therapies. Six of them showed initial decrease of seizure frequency and severity and maintained improvement in some neurodevelopmental skills.Interpretation: A considerable number of patients showed neurotransmitter abnormalities. Age at seizure onset and duration of epilepsy before CSF study were the principal factors related to neurotransmitter depletion. Early monoamine supplementation would seem advisable as a neuroprotective strategy.What this paper adds: 5‐Hydroxyindoleacetic acid homeostasis is especially vulnerable in patients with epileptic encephalopathy/developmental and epileptic encephalopathy. Age of seizure onset and duration of epilepsy are determinants of neurotransmitter depletion.Keywords
Funding Information
- European Regional Development Fund
This publication has 30 references indexed in Scilit:
- Glia and epilepsy: excitability and inflammationTrends in Neurosciences, 2013
- The monoamine neurotransmitter disorders: an expanding range of neurological syndromesThe Lancet Neurology, 2011
- The serotonin axis: Shared mechanisms in seizures, depression, and SUDEPEpilepsia, 2011
- Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11C]WAY-100635 PET studyEpilepsy & Behavior, 2010
- Cerebrospinal fluid alterations of the serotonin product, 5‐hydroxyindolacetic acid, in neurological disordersJournal of Inherited Metabolic Disease, 2010
- Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatmentBrain and Development, 2009
- Clinical Utility of Monoamine Neurotransmitter Metabolite Analysis in Cerebrospinal FluidClinical Chemistry, 2008
- Secondary abnormalities of neurotransmitters in infants with neurological disordersDevelopmental Medicine & Child Neurology, 2007
- HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterinsJournal of Neuroscience Methods, 2005
- Monoamines and their metabolites in cerebrospinal fluid and temporal cortex of epileptic patientsEpilepsy Research, 1996